Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the ...
MedPage Today on MSN3d
Topical JAK Inhibitor Active in Itchy Prurigo NodularisMore than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of starting ...
Zacks Investment Research on MSN4d
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis StudiesIncyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ...
Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and ...
As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...
Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ...
The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...
Patients with chronic prurigo suffer from anxiety, depression, suicidal ideation, stigmatization, stress and body dysmorphic disorder. Each comorbidity had predictors including younger age and ...
Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ruxolitinib cream 1.5% in adults with prurigo nodularis (PN). The data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback